EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application

Aljoscha Gabelmann, Claus-Michael Lehr iD, Holger Grohganz iD

Pharmaceutics · 23.05.2023 · 15 (6) · 1574

DOI: 10.3390/pharmaceutics15061574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.05.2023. Verfasst von Aljoscha Gabelmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Addressing antimicrobial resistance requires new approaches in various disciplines of pharmaceutical sciences. The fluoroquinolone levofloxacin (LEV) plays an important role in the therapy of lung infections. However, its effectiveness is limited by its severe side effects involving tendinopathy, muscle weakness and psychiatric disturbance. Therefore, there is a need for the development of an effective formulation of LEV with reduced systemic drug concentrations, thereby also reducing the consumption and excretion of antibiotics or metabolites. This study aimed for the development of a pulmonary-applicable LEV formulation. Co-amorphous LEV-L-arginine (ARG) particles were prepared by spray drying and characterised by scanning electron microscopy, modulated differential scanning calorimetry, X-ray powder diffraction, Fourier-transform infrared spectroscopy and next generation impactor analysis. Co-amorphous LEV-ARG salts were produced independently of varying process parameters. The use of 30% (v/v) ethanol as a solvent led to better aerodynamic properties compared to an aqueous solution. With a mass median aerodynamic diameter of just over 2 µm, a fine particle fraction of over 50% and an emitted dose of over 95%, the product was deemed suitable for a pulmonary application. The created process was robust towards the influence of temperature and feed rate, as changing these parameters did not have a significant influence on the critical quality attributes, indicating the feasibility of producing pulmonary-applicable co-amorphous particles for sustainable antibiotic therapy.

Schlagwörter

Stichwörter der Autor:innen

aerosolsco-amorphousdry powder inhalationparticle sizeprocessspray dryingsustainability

Autor:innen und Institutionen

  • Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
  • Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany.
  • Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University, Campus E81, 66123 Saarbrücken, Germany.

ORCID-Profile: Claus-Michael Lehr, Holger Grohganz

Zitieren

APA

Gabelmann, A., Lehr, C. M., & Grohganz, H. (2023). Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application. Pharmaceutics, 15(6), 1574. https://doi.org/10.3390/pharmaceutics15061574

Vancouver

Gabelmann A, Lehr CM, Grohganz H. Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application. Pharmaceutics. 2023;15(6):1574. doi:10.3390/pharmaceutics15061574

BibTeX
@article{Gabelmann2023,
  author = {Gabelmann, Aljoscha and Lehr, Claus-Michael and Grohganz, Holger},
  title = {Preparation of Co-Amorphous Levofloxacin Systems for Pulmonary Application},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1574},
  doi = {10.3390/pharmaceutics15061574}
}
Kostenlos starten →